Skip to main content

Table 1 Characteristics and baseline demographics of healthy volunteers and pulmonary fibrosis patients in study 1

From: Dysregulated metabolic pathways of pulmonary fibrosis and the lipids associated with the effects of nintedanib therapy

Parameters

Healthy volunteers (n=63)

Pulmonry fibrosis (n=66)

P value

Age, years

65, (58-72)

72, (67-77)

p<0.05

Gender, Male/Female

38/25

55/11

p<0.05

Smoking history, pack-years

 

20 (3.0-40.0)

 

Current, former, never, (%)

 

3, 75.8, 21.2

 

BMI

 

23.0, (19.5-25.5)

 

BSA (m2)

 

1.65 (1.50-1.74)

 

FEV1/FVC (G)(%)

 

85.8 (80.2-91.7)

 

FVC (ml)

 

2070 (1705-2535)

 

%FVC (%)

 

67.2 (57.6-81.1)

 

mMRC

 

2 (0-3)

 

KL-6 (U/mL)

 

1120 (660.0-1775)

 

Comorbidities, n (%)

   

Hypertension

 

17 (25.8)

 

Diabetes Mellitus

 

16 (24.2)

 

Hyper lipidemia

 

9 (13.6)

 

Benign prostatic hyperplasia

 

7 (10.6)

 

Hyperuricemia

 

5 (7.6)

 

Chronic kidney disease

 

4 (6.1)

 
  1. Data were expressed as mean and interquartile range (IQR)